GUTS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 5.21%, SMA50 -67.18%, SMA200 -67.99%). The stock’s 14-day RSI is 27.15 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.33% below its high and over 25.85% above its low. Average 10-day trading volume of 1.39 million shares is below the 3-month average of 1.97 million, indicating normal recent market interest.

Fractyl Health, Inc. Common Stock has 70.88 million shares outstanding. The public float is 27.94 million shares, elevated short interest at 8.20% of float. This equals 2.00 million shares. The short ratio is 8.02 days. Institutional investors hold 55.71% of the float. Insiders own 3.34%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Fractyl Health, Inc. Common Stock generated EPS of -$2.27 over the past year. Five-year average earnings growth is -12.32%. Wall Street analysts project EPS growth of 26.37% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $2.00. The high target offers 1084.21% upside. The low target suggests 163.16% downside. The mean target is $6.73. This offers 785.53% upside. Fractyl Health, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -135.29%. The prior quarter beat by -178.95%. Over the last six quarters, Apple has recorded several small beats. These include 18.18% in March 03, 2025.

Fractyl Health, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) closed at $0.76 USD, losing -$0.03 (-3.76%) from the previous close of $0.79. The stock is currently mid-range between its 52-week high and low $0.38 and $3.03. With a market capitalization of about $54.87 million, Fractyl Health, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~2.11). Key stats such as the average daily volume over the past year has been around 2.14 million shares, volume is running light vs its 52-week average. Headquartered in Lexington, MA, Fractyl Health, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Harith Rajagopalan, the company employs approximately 107 people and listed since February 02, 2024. Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) shares are down -13.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Fractyl Health, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.06, suggesting 828.95% upside. Our AI forecast model points to short-term strength (13.16% over two weeks), a medium-term fall (-93.42% over three months), and a longer-term loss (-22.37% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Fractyl Health, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.16%, with price expected at $0.86 by June 17, 2026, within a range of $0.79 to $0.92 3-Month Outlook: Projected fall of -93.42%, reaching $0.05 by September 01, 2026, with a range of $0.00 to $0.11. 1-Year Outlook: Projected loss of -22.37%, with price at $0.59 by June 03, 2027, within a range of $0.00 to $0.28.

Fractyl Health, Inc. Common Stock trades at a P/E ratio of -0.54, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.71 suggesting the stock is closer to book value. The P/FCF stands at -0.63, also above market averages.